These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37178051)

  • 41. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation with Coronary or Peripheral Artery Disease.
    Zhang H; Xue Z; Yi D; Li X; Tan Y; Li J
    Int Heart J; 2020 Mar; 61(2):231-238. PubMed ID: 32173695
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis.
    Telles-Garcia N; Dahal K; Kocherla C; Lip GYH; Reddy P; Dominic P
    Int J Cardiol; 2018 Oct; 268():143-148. PubMed ID: 30041779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of non-vitamin K antagonist oral anticoagulants versus warfarin in heart failure patients with atrial fibrillation.
    Chen F; Zhou Y; Wan Q; Yu P; Ma J; Hu J
    Heart Fail Rev; 2021 Nov; 26(6):1391-1397. PubMed ID: 32249407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.
    Carnicelli AP; Hong H; Giugliano RP; Connolly SJ; Eikelboom J; Patel MR; Wallentin L; Morrow DA; Wojdyla D; Hua K; Hohnloser SH; Oldgren J; Ruff CT; Piccini JP; Lopes RD; Alexander JH; Granger CB;
    Am Heart J; 2021 Mar; 233():48-58. PubMed ID: 33296688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation.
    Madzak A; Larsen TB; Lane DA; Lip GY; Nielsen PB
    Expert Rev Cardiovasc Ther; 2015 Oct; 13(10):1155-63. PubMed ID: 26401923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis.
    Li Z; Zheng Y; Li D; Wang X; Cheng S; Luo X; Wen A
    Anatol J Cardiol; 2022 Jun; 26(6):424-433. PubMed ID: 35703478
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety outcomes of patients with atrial fibrillation compared between warfarin and non-vitamin K antagonist oral anticoagulants based on SAMe-TT
    Methavigul K; Yindeengam A; Krittayaphong R
    BMC Cardiovasc Disord; 2023 Jan; 23(1):43. PubMed ID: 36690928
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Warfarin compared with non-vitamin K antagonist oral anticoagulants in subjects with liver disease and atrial fibrillation: A meta-analysis.
    Su T; Fu Z; Nie Z; Guo D
    Int J Clin Pract; 2021 Oct; 75(10):e14585. PubMed ID: 34192400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis.
    Lee KH; Chen YF; Yeh WY; Yeh JT; Yang TH; Chou CY; Chang YL; Wang WT; Chiang CE; Chen CH; Cheng HM
    Age Ageing; 2022 Dec; 51(12):. PubMed ID: 36571776
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis.
    Memon MM; Siddiqui AA; Amin E; Shaikh FN; Khan MS; Doukky R; Krasuski RA
    Catheter Cardiovasc Interv; 2022 Jun; 99(7):2101-2110. PubMed ID: 35476221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of novel oral anticoagulants in patients with atrial nonvalvular atrial fibrillation and diabetes mellitus: a systematic review and meta-analysis.
    Jia X; Yin Z; Zhang W; Du S; Kang J
    J Transl Med; 2022 Sep; 20(1):441. PubMed ID: 36180856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
    Gieling EM; van den Ham HA; van Onzenoort H; Bos J; Kramers C; de Boer A; de Vries F; Burden AM
    Br J Clin Pharmacol; 2017 Aug; 83(8):1844-1859. PubMed ID: 28205318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials.
    Zelniker TA; Ruff CT; Antman EM; Giugliano RP
    Eur Heart J Acute Cardiovasc Care; 2019 Sep; 8(6):554-561. PubMed ID: 30318902
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis.
    Santarpia G; De Rosa S; Polimeni A; Giampà S; Micieli M; Curcio A; Indolfi C
    PLoS One; 2015; 10(5):e0126512. PubMed ID: 25974377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials.
    Harskamp RE; Lucassen WAM; Lopes RD; Himmelreich JCL; Parati G; Weert HCPMV
    Acta Cardiol; 2022 May; 77(3):191-195. PubMed ID: 33685380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of transesophageal echocardiography findings after different anticoagulation strategies in patients with atrial fibrillation: a systematic review and meta-analysis.
    Yang J; Zhang X; Wang XY; Zhang C; Chen SZ; Hu SJ
    BMC Cardiovasc Disord; 2019 Nov; 19(1):261. PubMed ID: 31771529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.